Cantor Fitzgerald Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price

Janux Therapeutics (NASDAQ:JANX) had its target price lowered by analysts at Cantor Fitzgerald from $150.00 to $100.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock.

A number of other equities research analysts have also weighed in on the stock. Wedbush reiterated an “outperform” rating and set a $45.00 target price (down from $76.00) on shares of Janux Therapeutics in a research note on Tuesday, December 2nd. Piper Sandler reduced their price objective on Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday, January 16th. HC Wainwright reduced their price target on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, December 2nd. Stifel Nicolaus dropped their price objective on shares of Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. Finally, Wolfe Research initiated coverage on shares of Janux Therapeutics in a report on Tuesday, November 18th. They set a “peer perform” rating for the company. Eleven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $55.58.

Janux Therapeutics Stock Down 2.2%

JANX traded down $0.30 during midday trading on Friday, hitting $13.50. 30,439 shares of the company traded hands, compared to its average volume of 1,410,446. The company’s 50-day moving average is $13.73 and its 200 day moving average is $20.80. The firm has a market capitalization of $811.78 million, a PE ratio of -8.03 and a beta of 2.88. Janux Therapeutics has a 52 week low of $12.12 and a 52 week high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.14. The company had revenue of $7.88 million during the quarter, compared to the consensus estimate of $0.08 million. On average, sell-side analysts predict that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

Insider Activity at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 1,879 shares of Janux Therapeutics stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $25,798.67. Following the completion of the transaction, the insider directly owned 83,095 shares of the company’s stock, valued at approximately $1,140,894.35. The trade was a 2.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Thomas Diraimondo sold 2,505 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $34,393.65. Following the completion of the transaction, the insider directly owned 124,425 shares in the company, valued at $1,708,355.25. This represents a 1.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 22,366 shares of company stock valued at $371,245 in the last ninety days. 8.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Janux Therapeutics

Institutional investors have recently modified their holdings of the company. AQR Capital Management LLC boosted its holdings in Janux Therapeutics by 71.7% during the first quarter. AQR Capital Management LLC now owns 9,717 shares of the company’s stock worth $262,000 after buying an additional 4,059 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Janux Therapeutics by 18.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,403 shares of the company’s stock worth $583,000 after purchasing an additional 3,393 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Janux Therapeutics by 12.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 186,394 shares of the company’s stock valued at $5,033,000 after purchasing an additional 20,657 shares during the last quarter. AlphaQuest LLC boosted its position in shares of Janux Therapeutics by 3,658.9% in the 2nd quarter. AlphaQuest LLC now owns 9,698 shares of the company’s stock valued at $224,000 after purchasing an additional 9,440 shares during the period. Finally, Y Intercept Hong Kong Ltd increased its stake in Janux Therapeutics by 15.5% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 20,602 shares of the company’s stock worth $476,000 after purchasing an additional 2,769 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.